Aprea Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Update on Business Operations
16 mars 2021 16h15 HE
|
Aprea Therapeutics
BOSTON, March 16, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate...
Aprea Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021
08 janv. 2021 08h00 HE
|
Aprea Therapeutics
BOSTON, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the...
PMV Pharma Doses First Patient in Phase 1/2 Study of PC14586, a First-in-Class Precision Oncology Therapy That Targets Mutant p53
23 nov. 2020 08h00 HE
|
PMV Pharmaceuticals, Inc.
PC14586 targets p53 Y220C mutants to selectively reactivate p53, restoring the protein’s tumor-suppressing functionPhase 1/2 study is enrolling patients with advanced solid tumors that have a p53...
Aprea Therapeutics to Participate in the 32nd Annual Piper Sandler Healthcare Conference
19 nov. 2020 08h00 HE
|
Aprea Therapeutics
BOSTON, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the...
Aprea Therapeutics Reports Third Quarter 2020 Financial Results and Provides Update on Business Operations
05 nov. 2020 16h15 HE
|
Aprea Therapeutics
BOSTON, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the...
Aprea Therapeutics to Highlight Changing Treatment Paradigm in MDS as well as Development Pipeline Progress at Virtual R&D Day Today
30 oct. 2020 04h00 HE
|
Aprea Therapeutics
BOSTON, Oct. 30, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics to reactivate...
Aprea Therapeutics Launches Disease Awareness Website for Healthcare Professionals, p53reactivation.com
14 oct. 2020 08h00 HE
|
Aprea Therapeutics
BOSTON, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics to reactivate...
PMV Pharma Granted FDA Fast Track Designation of PC14586 for the Treatment of Advanced Cancer Patients that have Tumors with a p53 Y220C Mutation
13 oct. 2020 08h00 HE
|
PMV Pharmaceuticals, Inc.
CRANBURY, N.J., Oct. 13, 2020 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc., (Nasdaq: PMVP) a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic...
Aprea Therapeutics Receives OK from FDA to Initiate Phase 1 Clinical Studies for Next-Generation Mutant p53 Reactivator, APR-548
07 oct. 2020 08h00 HE
|
Aprea Therapeutics
BOSTON, Oct. 07, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics Inc., (NASDAQ: APRE), a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapeutics that...
Aprea Therapeutics Appoints Michael A. Kelly to Board of Directors
29 sept. 2020 08h00 HE
|
Aprea Therapeutics
BOSTON, Sept. 29, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics Inc., (NASDAQ: APRE), a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapeutics that...